Heart failure is a progressive condition characterised by cardiomyocyte loss and cardiac fibroblast proliferation leading to cardiac hypertrophy and impaired heart function. Cardiac hypertrophy is commonly associated with high blood pressure in response to altered renin-angiotensin system (RAS) activity. However, there is evidence that RAS activity has a role in the early stages of heart failure that is independent of its influence on blood pressure. To investigate this, Justin F. X. Ainscough's group used a conditional mouse model in which a human angiotensin II type-I receptor transgene (HART) was expressed in fully matured cardiomyocytes. Persistent HART activity in young mice causes heart dysfunction without cardiac hypertrophy. This dysfunction correlates with increased expression of pro-angiogenic markers in cardiomyocytes and elicits a compensatory response in non-myocyte cells, which show downregulation of pro-angiogenic genes and inflammatory markers. Noteworthy, this stage is reversible by downregulation of HART expression. Further activation of the receptors, instead, leads to a secondary stage characterised by cardiomyocyte death and activation of fibroblast and inflammatory cells, which leads to further deterioration of heart function. This study therefore identifies an early stage of heart dysfunction associated with increased RAS activity, potentially treatable with RAS inhibitors to prevent heart failure development. Page
Skip Nav Destination
Article navigation
August 2015
Virtual Meeting - Developmental Disorders: From Mechanism to Treatment
A collaboration between the Development and Disease Models & Mechanisms journal teams, this virtual Meeting will unite developmental biologists, human geneticists and clinical researchers to focus on building bridges from bench to clinic. Register your interest and find out more.
High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition
Vitamin B1 is shown to prevent nutrition-induced fatty liver in our current Editor’s choice by Hay Davir and his colleagues, when they use sheep as a large-animal model for studying the disease.
Find out more in an interview with the paper's first authors, Mugagga Kalyesubula and Ramgopal Mopuri.
Upcoming grant deadlines
Call for papers - The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is welcoming submissions until 3 May 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on targeting the RAS pathway.
Social media
